Trials / Active Not Recruiting
Active Not RecruitingNCT06521567
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 0 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Conditions
- Melanoma
- Hodgkin Lymphoma
- High and Low Grade Glioma
- Glioblastoma Multiforme (GBM)
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Ependymoma
- Osteosarcoma
- Hepatic Tumors
- Hepatoblastoma
- Hepatocellular Carcinoma (HCC)
- Fibrolamellar Carcinoma
- Rhabdomyosarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cobolimab | Cobolimab will be administered |
| DRUG | Dostarlimab | Dostarlimab will be administered |
Timeline
- Start date
- 2025-03-06
- Primary completion
- 2026-10-13
- Completion
- 2026-10-13
- First posted
- 2024-07-26
- Last updated
- 2025-11-12
Locations
20 sites across 6 countries: United States, Czechia, Denmark, France, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06521567. Inclusion in this directory is not an endorsement.